2011-11-02 03:03:21 - New Pharmaceuticals research report from GlobalData is now available from Fast Market Research

Atherosclerosis or Coronary Artery Disease Therapeutics (CAD) - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Atherosclerosis or Coronary Artery Disease Therapeutics (CAD) - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market. The report identifies the key trends shaping and driving the global Atherosclerosis or Coronary Artery Disease (CAD) market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Atherosclerosis or

Coronary Artery Disease (CAD) sector. This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData's team of industry experts.


Full Report Details at
- www.fastmr.com/prod/269473_atherosclerosis_or_coronary_artery_di ..


GlobalData analysis shows that the global Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market stood at $12.0 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 3.5% to reach $14.2 billion in 2010. GlobalData forecasts that the global CAD therapeutics market will grow at a CAGR of 1.0% over the next eight years to reach $15,432.2m by 2018. The Atherosclerosis or Coronary Artery Disease (CAD) therapeutics markert is comprised of statins, angiotensin-converting enzyme (ACE) inhibitors, beta blokers (BB), antiplatlets, calcium channel blockers (CCBs) and nitrates. The growth in CAD therapeutics market is mainly driven by increased prevalence, sedentary lifestyle obesity, hypertension, dyslipidemia, particularly reduction in high density cholesterol (HDL-C) and high cholesterol diet. The mentioned causative factors are responsible for increasing number of patients with CAD or likely develop in future. With the launch of first-in-class pipeline molecules such as Darapladib, Dalcetrapib (RG1658), Mipomersen (ISIS 301012), Vorapaxar (SCH 530348), Canakinumab (ACZ885), Varespladib (A 002), Aliskiren, Generx, Xarelto (rivaroxaban) and Anacetrapib (MK0859) these are expected to get launched in forecasting period. New entrants in the CAD therapeutics market have shown increased efficacy and safety profiles along with reduction of CHD risk factors.

The treatment options for CAD patients are drugs such as Lipitor (atorvastatin calicium), Crestor (rosuvastatin calcium), Angiomax (bivalirudin), Plavix (clopidogrel bisulfate), Effient (prasugrel), Norvasc (amlodipine) and Altace (ramipril). The impending patent expiry of Lipitor in November 2011; Plavix, Effient and Angiomax in 2012 and Crestor in 2016 means patients will have access to treatment at much lower prices reflecting brand erosion of these drugs. The patent expiries of Lipitor, Crestor, Plavix and Effient will show an impact in the CAD theapeutics market during the forecast period.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market. Its scope includes -

* Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan); Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2018.
* Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. The pipeline for Atherosclerosis or Coronary Artery Disease (CAD) has novel therapies with mechanis of action such as CETP inhibitors, Interleukin-1B inhibitor, FXR Inhibitors, P2Y12ADP receptor antagonist, SREBP2 activator and p38 kinase inhibitors.
* Analysis of the current and future competition in the seven key countries' Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market. The key market players for Atherosclerosis or Coronary Artery Disease (CAD) in future will be GlaxoSmithKline plc, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Isis Pharmaceuticals, Inc, Anthera Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The Medicine Company and Cardium Therapeutics
* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
* Key topics covered include strategic competitor assessment, market characterization, unmet needs, and the implications for the Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market.
* Analysis of key recent licensing and partnership agreements in the Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

* Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
* Develop business strategies by understanding the trends shaping and driving the global Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market.
* Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market in future.
* Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
* About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.